(Q34182143)

31 July 2017

1 reference

title

Thalidomide: a remarkable comeback (English)

1 reference

31 July 2017

0 references

Jacobson JM

1

1 reference

PubMed ID

11249521

31 July 2017

language of work or name

English

0 references

publication date

1 May 2000

1 reference

Expert Opinion on Pharmacotherapy

31 July 2017

1 reference

31 July 2017

1

1 reference

31 July 2017

4

1 reference

31 July 2017

849-863

1 reference

Rediscovering thalidomide: a review of its mechanism of action, side effects, and potential uses

31 July 2017

1 reference

https://api.crossref.org/works/10.1517%2F14656566.1.4.849

Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.1.4.849

Thalidomide inhibits the replication of human immunodeficiency virus type 1

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.1.4.849

Prolonged treatment with recombinant interferon gamma induces erythema nodosum leprosum in lepromatous leprosy patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.1.4.849

Tumor necrosis factor alpha production enhancers with a phenylphthalimide skeleton

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.1.4.849

Thalidomide is an inhibitor of angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.1.4.849

Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.1.4.849

Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.1.4.849

Thalidomide for the treatment of esophageal aphthous ulcers in patients with human immunodeficiency virus infection. National Institute of Allergy and Infectious Disease AIDS Clinical Trials Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.1.4.849

Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.1.4.849

The metabolic and immunologic effects of short-term thalidomide treatment of patients infected with the human immunodeficiency virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.1.4.849

Enantiomers of thalidomide: blood distribution and the influence of serum albumin on chiral inversion and hydrolysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.1.4.849

Thalidomide: rationale for renewed use in immunological disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.1.4.849

Thalidomide teratogenesis: evidence for a toxic arene oxide metabolite

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.1.4.849

IgG antibody subclasses, tumor necrosis factor and IFN-gamma levels in patients with type II lepra reaction on thalidomide treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.1.4.849

Thalidomide as treatment of refractory aphthous ulceration related to human immunodeficiency virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.1.4.849

The role of cytokines in the immune response to tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.1.4.849

Thalidomide therapy for patients with refractory Crohn's disease: an open-label trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.1.4.849

An open-label pilot study of low-dose thalidomide in chronically active, steroid-dependent Crohn's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.1.4.849

Antitumor activity of thalidomide in refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.1.4.849

Thalidomide neurotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.1.4.849

Development of polyneuropathy during thalidomide therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.1.4.849

Thalidomide revisited: pharmacology and clinical applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.1.4.849

Adverse reactions to thalidomide in patients infected with human immunodeficiency virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.1.4.849

Clinical experience with thalidomide in the management of severe oral and genital ulceration in conditions such as Behçet's disease: use of neurophysiological studies to detect thalidomide neuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.1.4.849

21 January 2018

Identifiers

DOI

10.1517/14656566.1.4.849

1 reference

31 July 2017

1 reference

PubMed ID

11249521